Iovance Biotherapeutics Inc (IOVA)

Feb 21, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Feb 21, 2025

Feb 21, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 21, 2025

Feb 21, 2025

Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Rice Hall James & Associates LLC - MarketBeat

Feb 20, 2025

Feb 20, 2025

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know - Nasdaq

Feb 20, 2025

Feb 20, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA) - ACCESS Newswire

Feb 20, 2025

Feb 20, 2025

My 3 Favorite Stocks to Buy Right Now - The Motley Fool

Feb 20, 2025

Feb 19, 2025

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) - MSN

Feb 19, 2025

Feb 18, 2025

Iovance Biotherapeutics to Report Fourth Quarter and Full - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

Biotech Spotlight: Iovance's Crucial Year-End Results & TIL Therapy Updates Coming Feb 27 - StockTitan

Feb 18, 2025

Feb 18, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3%Time to Buy? - MarketBeat

Feb 18, 2025

Feb 17, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Banque Pictet & Cie SA - MarketBeat

Feb 17, 2025

Feb 14, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year LowShould You Sell? - MarketBeat

Feb 14, 2025

Feb 12, 2025

Executive Compensation Alert: Iovance's Strategic Move with 305K Share Package for Commercial Chief - StockTitan

Feb 12, 2025

Feb 12, 2025

Stifel maintains Buy on Iovance Biotherapeutics, target at $21 - MSN

Feb 12, 2025

Feb 12, 2025

Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL

Feb 12, 2025

Feb 12, 2025

(IOVA) Trading Report - Stock Traders Daily

Feb 12, 2025

Feb 12, 2025

Iovance Biotherapeutics appoints new chief commercial officer - MSN

Feb 12, 2025

Feb 11, 2025

Jennison Associates LLC Buys Shares of 66,568 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Feb 11, 2025

Feb 10, 2025

Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma - Marketscreener.com

Feb 10, 2025

Feb 10, 2025

Iovance Biotherapeutics Shares Fell Today: What's Going On? - Benzinga

Feb 10, 2025

Feb 10, 2025

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - br.ADVFN.com

Feb 10, 2025

Feb 10, 2025

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - GlobeNewswire

Feb 10, 2025

Feb 10, 2025

Iovance Lands Former Celgene & BMS Executive to Accelerate TIL Therapy Commercialization | $IOVA - StockTitan

Feb 10, 2025

Feb 08, 2025

What's Going On With Iovance Biotherapeutics Today? - MSN

Feb 08, 2025

Feb 07, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low on Analyst Downgrade - MarketBeat

Feb 07, 2025

Feb 06, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low on Analyst Downgrade - MarketBeat

Feb 06, 2025

Feb 06, 2025

SG Americas Securities LLC Purchases Shares of 69,625 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Feb 06, 2025

Feb 04, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $7.50 at Piper Sandler - MarketBeat

Feb 04, 2025

Feb 03, 2025

Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq

Feb 03, 2025

Feb 03, 2025

IOVA stock touches 52-week low at $5.57 amid market challenges - Investing.com

Feb 03, 2025

Feb 02, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 Consensus Target Price from Analysts - MarketBeat

Feb 02, 2025

Feb 01, 2025

What's Wrong With Iovance Biotherapeutics Stock? - MSN

Feb 01, 2025

Feb 01, 2025

Institutional owners may consider drastic measures as Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) recent US$122m drop adds to long-term losses - Simply Wall St

Feb 01, 2025

Feb 01, 2025

(IOVA) Investment Report - Stock Traders Daily

Feb 01, 2025

Feb 01, 2025

Lion Biotechnologies, Inc. Appoints Michael T. Lotze, MD, as Chief Scientific Officer and Vice President of Research and Development - Marketscreener.com

Feb 01, 2025

Jan 31, 2025

Stifel maintains Buy on Iovance stock with $21 target - MSN

Jan 31, 2025

Jan 29, 2025

Where Will Iovance Biotherapeutics Be in 5 Years? - MSN

Jan 29, 2025

Jan 28, 2025

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Jan 28, 2025

Jan 28, 2025

Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment - TipRanks

Jan 28, 2025